Prague Med. Rep. 2012, 113, 136-146
https://doi.org/10.14712/23362936.2015.28
Novel Mutations in the Tyrosine Hydroxylase Gene in the First Czech Patient with Tyrosine Hydroxylase Deficiency
References
1. 2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur. J. Neurol. 13, 433–444.
< , A., Barnes, M. P., Bhatia, K. P., Fernandez-Alvarez, E., Filippini, G., Gasser, T., Krauss, J. K., Newton, A., Rektor, I., Savoiardo, M., Valls-Solè, J. (https://doi.org/10.1111/j.1468-1331.2006.01537.x>
2. 1984) Amine metabolites in the cerebrospinal fluid as a measure of central neurotransmitter function: methodological aspects. Adv. Biochem. Psychopharmacol. 39, 27–34.
, L., Asberg, M. (
3. 1998) Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin. Chem. 44, 1897–1904.
< , C., Wevers, R. A., Jansen, R. J., Smeitink, J. A., de Rijk-van Andel, J. F., Gabreels, F. J., Hoffmann, G. F. (https://doi.org/10.1093/clinchem/44.9.1897>
4. 1994) High-performance liquid chromatographic measurement of cerebrospinal fluid tetrahydrobiopterin, neopterin, homovanillic acid and 5-hydroxindoleacetic acid in neurological diseases. J. Chromatogr. B Biomed. Appl. 657, 61–66.
< , M., Nagatsu, T., Chambon, P., Chatel, M. (https://doi.org/10.1016/0378-4347(94)80070-7>
5. 2006) Mitochondrial trafficking to synapses in cultured primary cortical neurons. J. Neurosci. 26, 7035–7045.
< , D. T., Honick, A. S., Reynolds, I. J. (https://doi.org/10.1523/JNEUROSCI.1012-06.2006>
<PubMed>
6. 2006) Cerebrospinal fluid monoamine metabolite levels in human newborn infants born in winter differ from those born in summer. Psychiatry Res. 145, 189–197.
< , J., Murphy, D. L., Constantino, J. N. (https://doi.org/10.1016/j.psychres.2005.11.008>
7. 2010) Cerebrospinal fluid alterations of the serotonin product, 5-hydroxyindolacetic acid, in neurological disorders. J. Inherit. Metab. Dis. 33, 803–809.
< , E., Serrano, M., Pérez-Dueñas, B., Ormazábal, A., Montero, R., Veneselli, E., Pineda, M., González, V., Sanmartí, F., Fons, C., Sans, A., Cormand, B., Puelles, L., Alonso, A., Campistol, J., Artuch, R., García-Cazorla, A. (https://doi.org/10.1007/s10545-010-9200-9>
8. 2007) Secondary abnormalities of neurotransmitters in infants with neurological disorders. Dev. Med. Child Neurol. 49, 740–744.
< , A., Serrano, M., Pérez-Dueñas, B., González, V., Ormazábal, A., Pineda, M., Fernández-Alvarez, E., Campistol, J. M., Artuch, R. M. (https://doi.org/10.1111/j.1469-8749.2007.00740.x>
9. 2008) Mitochondrial diseases mimicking neurotransmitter defects. Mitochondrion 8, 273–278.
< , A., Duarte, S., Serrano, M., Nascimento, A., Ormazabal, A., Carrilho, I., Briones, P., Montoya, J., Garesse, R., Sala-Castellvi, P., Pineda, M., Artuch, R. (https://doi.org/10.1016/j.mito.2008.05.001>
10. 2002) Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy. Mov. Disord. 17, 354–359.
< , P. J., Wevers, R. A., Steenbergen-Spanjers, G. C., Fung, V. S., Earl, J., Wilcken, B. (https://doi.org/10.1002/mds.10095>
11. 2007) Dyskinetic cerebral palsy: a population-based study of children born between 1991 and 1998. Dev. Med. Child Neurol. 49, 246–251.
< , K., Hagberg, G., Wiklund, L. M., Eek, M. N., Uvebrant, P. (https://doi.org/10.1111/j.1469-8749.2007.00246.x>
12. 2009) Dyskinetic cerebral palsy in Europe: trends in prevalence and severity. Arch. Dis. Child. 94, 921–926.
< , K., McManus, V., Hagberg, G., Uvebrant, P., Krägeloh-Mann, I., Cans, C.; SCPE collaboration (https://doi.org/10.1136/adc.2008.144014>
13. 2003) Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann. Neurol. 54, 56–65.
< , G. F., Assmann, B., Bräutigam, C., Dionisi-Vici, C., Häussler, M., de Klerk, J. B., Naumann, M., Steenbergen-Spanjers, G. C., Strassburg, H. M., Wevers, R. A. (https://doi.org/10.1002/ana.10632>
14. 1999) Presentation, diagnosis, and treatment of the disorders of monoamine neurotransmitter metabolism. Semin. Perinatol. 23, 194–203.
< , K. (https://doi.org/10.1016/S0146-0005(99)80051-2>
15. 2008) Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid. Clin. Chem. 54, 633–641.
< , K. (https://doi.org/10.1373/clinchem.2007.099986>
16. 1993) Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr. Res. 34, 10–14.
< , K., Surtees, R. A., Heales, S. J., Bowron, A., Howells, D. W., Smith, I. (https://doi.org/10.1203/00006450-199307000-00003>
17. 1996) Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum. Mol. Genet. 5, 1023–1028.
< , B., Knappskog, P. M., Clayton, P. T., Surtees, R. A., Clelland, J. D., Heales, S. J., Brand, M. P., Bartholomé, K., Flatmark, T. (https://doi.org/10.1093/hmg/5.7.1023>
18. 2006) Mitochondria at the synapse. Neuroscientist 12, 291–299.
< , C. V., Verstreken, P. (https://doi.org/10.1177/1073858406287661>
19. 2008) Biochemical diagnosis of dopaminergic disturbances in paediatric patients: Analysis of cerebrospinal fluid homovanillic acid and other biogenic amines. Clin. Biochem. 41, 1306–1315.
< , I., Serrano, M., Ormazabal, A., Pérez-Dueñas, B., García-Cazorla, A., Campistol, J., Artuch, R. (https://doi.org/10.1016/j.clinbiochem.2008.08.077>
20. 2009) The monogenic primary dystonias. Brain 132, 2005–2025.
< , U. (https://doi.org/10.1093/brain/awp172>
21. 1998) Clinical and molecular genetics of primary dystonias. Neurogenetics 1, 165–177.
, U., Steinberger, D., Nemeth, A. H. (
22. 2005) HPLC with electrochemical and fluorescence detection procedures for the diagnosis of inborn errors of biogenic amines and pterins. J. Neurosci. Methods 142, 153–158.
< , A., Garcia-Cazorla, A., Fernandez, Y., Fernandez-Alvarez, E., Campistol, J., Artuch, R. (https://doi.org/10.1016/j.jneumeth.2004.08.007>
23. 2007) The pediatric neurotransmitter disorders. J. Child Neurol. 22, 606–616.
< , P. L., Taylor, J. L., Trzcinski, S., Sokohl, A. (https://doi.org/10.1177/0883073807302619>
24. 2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132, 365–386.
, S., Skaletsky, H. (
25. 2001) In-use stability of monoamine metabolites in human cerebrospinal fluid. J. Chromatogr. B Biomed. Sci. Appl. 760, 301–306.
< , J. R., Ekhator, N. N., Geracioti, T. D. Jr. (https://doi.org/10.1016/S0378-4347(01)00290-0>
26. Surveillance of Cerebral Palsy in Europe (SCPE) (2002) Prevalence and characteristics of children with cerebral palsy in Europe. Dev. Med. Child Neurol. 44, 633–640.
27. 2006) Dystonia. N. Engl. J. Med. 355, 818–829.
< , D., Simon, D. K. (https://doi.org/10.1056/NEJMra055549>
28. 2003) Decreased homovanillic acid concentrations in cerebrospinal fluid in children without a known defect in dopamine metabolism. Eur. J. Paediatr. Neurol. 7, 31–37.
< , J. C., Rotteveel, J. J., Wevers, R. A. (https://doi.org/10.1016/S1090-3798(02)00137-X>
29. 2010) Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 133, 1810–1822.
< , M. A., Verbeek, M. M., Kamsteeg, E. J., de Rijk-van Andel, J. F., Aeby, A., Blau, N., Burlina, A., Donati, M. A., Geurtz, B., Grattan-Smith, P. J., Haeussler, M., Hoffmann, G. F., Jung, H., de Klerk, J. B., van der Knaap, M. S., Kok, F., Leuzzi, V., de Lonlay, P., Megarbane, A., Monaghan, H., Renier, W. O., Rondot, P., Ryan, M. M., Seeger, J., Smeitink, J. A., Steenbergen-Spanjers, G. C., Wassmer, E., Weschke, B., Wijburg, F. A., Wilcken, B., Zafeiriou, D. I., Wevers, R. A. (https://doi.org/10.1093/brain/awq087>